We have identified you may not be viewing TRAVAX optimally because the browser you are using is unsupported - click here.
We have identified you may not be viewing TRAVAX optimally because the browser you are using is unsupported - click here.
The Pan American Health Organization (PAHO) reports continuing widespread transmission of dengue fever in countries of the Americas and the Caribbean.
The following countries have reported dengue cases from 1 January 2024 to 21 February 2024:
Argentina: 21 850 cases (19 deaths)
Bolivia: 5 326 cases (6 deaths)
Bonaire, Saint Eustatius and Saba: 64 cases
Brazil: 664 785 cases (84 deaths)
Colombia: 34 026 cases
Costa Rica: 3 756 cases
Curaçao: 27 cases
French Guiana: 5 965 cases
Grenada: 53 cases
Guadeloupe: 1 445 cases
Guatemala: 4 861 cases
Honduras: 1 417 cases
Jamaica : 420 cases
Martinique: 1 630 cases
Mexico: 22 893 cases
Nicaragua: 17 339 cases
Panama: 2 609 cases (5 deaths)
Paraguay: 113 721 cases (24 deaths)
Peru: 13 010 cases (7 deaths)
Puerto Rico: 159 cases
Saint Barthelemy: 76 cases
Saint Kitts and Nevis: 119 cases
Saint Lucia: 3 cases
Saint Martin: 226 cases
Sint Maarten: 44 cases
Suriname: 30 cases (2 deaths)
United States of America: 94 cases (most are imported, although dengue has been transmitted in Florida in 2024)
Dengue virus is spread by Aedes mosquito bites and can cause a flu-like illness, sometimes leading to severe or life-threatening disease.
Dengue is an infection found in tropical and sub-tropical climates worldwide.
All travellers to endemic regions are potentially at risk of dengue fever and should be aware of this infection.
Aedes mosquitoes are particularly persistent and aggressive. They bite between dawn and dusk.
A new dengue vaccine Qdenga® has been licensed in the UK and is awaiting JCVI recommendations for use.
Travellers developing a fever during or on return from travel are advised to seek medical attention as soon as possible.
For further information see TRAVAX dengue fever page.
